The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

S. M. Keller, M. G. Vangel, S. Adak, Henry Wagner Jr., J. H. Schiller, A. Herskovic, R. Komaki, M. C. Perry, R. S. Marks, R. B. Livingston, D. H. Johnson

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P=0.12). The relative risk (RR) of death for men vs women was 1.19 (95% confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P=0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P=0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P<0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.

Original languageEnglish (US)
Pages (from-to)303-309
Number of pages7
JournalLung Cancer
Volume37
Issue number3
DOIs
StatePublished - Sep 1 2002

Fingerprint

Non-Small Cell Lung Carcinoma
Recurrence
Survival
Radiotherapy
Neoplasms
Therapeutics
Histology
Mutation
Adjuvant Radiotherapy
Etoposide
Cisplatin
Multivariate Analysis
Cross-Sectional Studies
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Keller, S. M. ; Vangel, M. G. ; Adak, S. ; Wagner Jr., Henry ; Schiller, J. H. ; Herskovic, A. ; Komaki, R. ; Perry, M. C. ; Marks, R. S. ; Livingston, R. B. ; Johnson, D. H. / The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. In: Lung Cancer. 2002 ; Vol. 37, No. 3. pp. 303-309.
@article{3d22d8b898bf4de09e6dc4c93b657621,
title = "The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer",
abstract = "This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P=0.12). The relative risk (RR) of death for men vs women was 1.19 (95{\%} confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P=0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P=0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P<0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.",
author = "Keller, {S. M.} and Vangel, {M. G.} and S. Adak and {Wagner Jr.}, Henry and Schiller, {J. H.} and A. Herskovic and R. Komaki and Perry, {M. C.} and Marks, {R. S.} and Livingston, {R. B.} and Johnson, {D. H.}",
year = "2002",
month = "9",
day = "1",
doi = "10.1016/S0169-5002(02)00103-4",
language = "English (US)",
volume = "37",
pages = "303--309",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Keller, SM, Vangel, MG, Adak, S, Wagner Jr., H, Schiller, JH, Herskovic, A, Komaki, R, Perry, MC, Marks, RS, Livingston, RB & Johnson, DH 2002, 'The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer', Lung Cancer, vol. 37, no. 3, pp. 303-309. https://doi.org/10.1016/S0169-5002(02)00103-4

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. / Keller, S. M.; Vangel, M. G.; Adak, S.; Wagner Jr., Henry; Schiller, J. H.; Herskovic, A.; Komaki, R.; Perry, M. C.; Marks, R. S.; Livingston, R. B.; Johnson, D. H.

In: Lung Cancer, Vol. 37, No. 3, 01.09.2002, p. 303-309.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

AU - Keller, S. M.

AU - Vangel, M. G.

AU - Adak, S.

AU - Wagner Jr., Henry

AU - Schiller, J. H.

AU - Herskovic, A.

AU - Komaki, R.

AU - Perry, M. C.

AU - Marks, R. S.

AU - Livingston, R. B.

AU - Johnson, D. H.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P=0.12). The relative risk (RR) of death for men vs women was 1.19 (95% confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P=0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P=0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P<0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.

AB - This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P=0.12). The relative risk (RR) of death for men vs women was 1.19 (95% confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P=0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P=0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P<0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.

UR - http://www.scopus.com/inward/record.url?scp=0036754178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036754178&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(02)00103-4

DO - 10.1016/S0169-5002(02)00103-4

M3 - Article

VL - 37

SP - 303

EP - 309

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -